186 related articles for article (PubMed ID: 11993688)
21. [Grading of neuroendocrine tumors].
Saeger W; Schnabel PA; Komminoth P
Pathologe; 2016 Jul; 37(4):304-13. PubMed ID: 27379621
[TBL] [Abstract][Full Text] [Related]
22. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease.
Grabowski P; Griss S; Arnold CN; Hörsch D; Göke R; Arnold R; Heine B; Stein H; Zeitz M; Scherübl H
Neuroendocrinology; 2005; 81(1):1-9. PubMed ID: 15809513
[TBL] [Abstract][Full Text] [Related]
23. Recent updates on grading and classification of neuroendocrine tumors.
Kim JY; Hong SM; Ro JY
Ann Diagn Pathol; 2017 Aug; 29():11-16. PubMed ID: 28807335
[TBL] [Abstract][Full Text] [Related]
24. Sporadically occurring functional pancreatic endocrine tumors: review of recent literature.
Goldin SB; Aston J; Wahi MM
Curr Opin Oncol; 2008 Jan; 20(1):25-33. PubMed ID: 18043253
[TBL] [Abstract][Full Text] [Related]
25. Subcutaneous fat necrosis as the presenting feature of a pancreatic carcinoma: the challenge of differentiating endocrine and acinar pancreatic neoplasms.
Martin SK; Agarwal G; Lynch GR
Pancreas; 2009 Mar; 38(2):219-22. PubMed ID: 19238022
[TBL] [Abstract][Full Text] [Related]
26. [Exocrine meets neuroendocrine: mimickers of pancreatic neuroendocrine neoplasms].
Karamitopoulou-Diamantis E
Pathologie (Heidelb); 2024 Feb; 45(1):42-49. PubMed ID: 38091082
[TBL] [Abstract][Full Text] [Related]
27. The role of cytomorphology and proliferative activity in predicting biologic behavior of pancreatic neuroendocrine tumors: a study by endoscopic ultrasound-guided fine-needle aspiration cytology.
Chatzipantelis P; Konstantinou P; Kaklamanos M; Apostolou G; Salla C
Cancer; 2009 Jun; 117(3):211-6. PubMed ID: 19350669
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis, histopathologic grading and prognostic moleculer marker analysis in patients with pancreatic neuroendocrine neoplasm].
Bao F; Chen GR; Hui P; Cai GP
Zhonghua Bing Li Xue Za Zhi; 2013 Jun; 42(6):426-32. PubMed ID: 24060085
[No Abstract] [Full Text] [Related]
29. [Neuroendocrine "silent" tumors of the pancreas].
Kubyshkin VA; Buriev IM; Abdulkerimov ZA; Gurevich LE; Kochatkov AV
Khirurgiia (Mosk); 2004; (3):4-9. PubMed ID: 15097980
[TBL] [Abstract][Full Text] [Related]
30. Solid-pseudopapillary neoplasm of the pancreas: awareness of unusual clinical presentations and morphology of the clear cell variant can prevent diagnostic errors.
Zhao P; deBrito P; Ozdemirli M; Sidawy MK
Diagn Cytopathol; 2013 Oct; 41(10):889-95. PubMed ID: 23584981
[TBL] [Abstract][Full Text] [Related]
31. The dilemma of "indeterminate" interpretations of pancreatic neuroendocrine tumors on fine needle aspiration.
Ahmed A; VandenBussche CJ; Ali SZ; Olson MT
Diagn Cytopathol; 2016 Jan; 44(1):10-3. PubMed ID: 26402138
[TBL] [Abstract][Full Text] [Related]
32. Clinical Presentation and Diagnosis of Pancreatic Neuroendocrine Tumors.
Anderson CW; Bennett JJ
Surg Oncol Clin N Am; 2016 Apr; 25(2):363-74. PubMed ID: 27013370
[TBL] [Abstract][Full Text] [Related]
33. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
Ardill JE; O'Dorisio TM
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
[TBL] [Abstract][Full Text] [Related]
34. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
[TBL] [Abstract][Full Text] [Related]
35. Molecular subtyping in pancreatic neuroendocrine neoplasms: New insights into clinical, pathological unmet needs and challenges.
Yan J; Yu S; Jia C; Li M; Chen J
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188367. PubMed ID: 32339609
[TBL] [Abstract][Full Text] [Related]
36. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
37. Duodeno-pancreatic neuroendocrine tumours.
Peros G; Sakorafas GH; Konstantoudakis G; Giannopoulos GA; Petropoulou K; Parasi A
Eur J Cancer Care (Engl); 2010 May; 19(3):393-402. PubMed ID: 19708940
[TBL] [Abstract][Full Text] [Related]
38. Molecular Characterization and Treatment of Pancreatic Neuroendocrine Tumors.
De Jesus-Acosta AMC
Oncology (Williston Park); 2019 Dec; 33(12):. PubMed ID: 31914198
[No Abstract] [Full Text] [Related]
39. Neuroendocrine neoplasms of the gastroenteropancreatic system: pathology and classification.
Anlauf M
Horm Metab Res; 2011 Nov; 43(12):825-31. PubMed ID: 22105474
[TBL] [Abstract][Full Text] [Related]
40. [Pancreatic endocrine tumors - management guidelines (recommended by the Polish Network of Neuroendocrine Tumors)].
Kos-Kudła B; Bolanowski M; Hubalewska-Dydejczyk A; Krzakowski M; Marek B; Nasierowska-Guttmejer A; Lampe P; Sworczak K;
Endokrynol Pol; 2008; 59(1):68-86. PubMed ID: 18335402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
